[1]
Hill, A.F. Organotransition Metal Chemistry; Royal Society of Chemistry: Cambridge, 2002.
[6]
Kaneoya, M.; Yoshida, N.; Uchida, M Transesterification in the presence of
hydrolases USPTO 4971909, 1990.
[16]
Tsukube, H. Crown Ethers and Analogous Compounds; Hiraoka, M., Ed.; Elsevier: New York, 1992, pp. 100-197.
[17]
Gokel, G.W.; Murillo, O. In Molecular Recognition: Receptors for Cationic Gursts, Comprehensive Supramolecular Chemistry; Pergamon Press: New York, 1996, Vol. 1, pp. 1-33.
[25]
Rahm, F. Chiral Pyridine-Containing Ligands for Asymmetric Catalysis: Synthesis and Applications., 2003.
[35]
(a) Sablong, R.; Newton, C.; Dierkes, P.; Osborn, J.A. Chiral tridentate C 2 diphosphine ligands for enantioselective catalysis.
Tetrahedron Lett., 1996,
37, 4933-4936.
[
http://dx.doi.org/10.1016/0040-4039(96)00968-9]
(b) Wei, D.; Bruneau-Voisine, A.; Chauvin, T.; Dorcet, V.; Roisnel, T.; Dmitry, A.V.; Lugan, N.; Sortais, J-B. Hydrogenation of Carbonyl Derivatives Catalysed by Manganese Complexes Bearing Bidentate Pyridinyl Phosphine Ligands.
Adv. Synth. Catal., 2018,
360, 676-68.
[
http://dx.doi.org/10.1002/adsc.201701115]
(c) Liu, J.J.; Galettis, P.; Farr, A.; Maharaj, L.; Samarasinha, H.; McGechan, A.C.; Baguley, B.C.; Bowen, R.J.; Berners-Price, S.J.; McKeage, M.J. In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake.
J. Inorg. Biochem., 2008,
102(2), 303-310.
[
http://dx.doi.org/10.1016/j.jinorgbio.2007.09.003] [PMID:
18029019]
(d) Wajda-Hermanowicz, K.; Ciunik, Z.; Kochel, A. Syntheses and molecular structure of some Rh and Ru complexes with the chelating diphenyl (2-pyridyl)phosphine ligand.
Inorg. Chem., 2006,
45(8), 3369-3377.
[
http://dx.doi.org/10.1021/ic051442k] [PMID:
16602796]
(e) Trofimov, B.A.; Artem’ev, A.V.; Malysheva, S.F.; Gusarova, N.K.; Belogorlova, N.S.; Korocheva, A.O.; Gatilov, Y.V.; Mamatyuk, V.I. Expedient one-pot organometallics-free synthesis of tris(2-pyridyl)phosphine from 2-bromopyridine and elemental phosphorus.
Tetrahedron Lett., 2012,
53, 2424-2427.
[
http://dx.doi.org/10.1016/j.tetlet.2012.03.004]
[36]
Hayashi, T.; Kawatsura, M.; Uozumi, Y. Retention of regiochemistry of allylic esters in palladium-catalyzed allylic alkylation in the presence of a MOP ligand. J. Am. Chem. Soc. 1998, 120, 1681-1687. Dierkes, P.; Ramdeehul, S.; Barloy, L.; Decian, A.; Fischer, J.; Kamer, P. C. J.; van Leeuwen, P. W. N. M.; Osborn, J. A. Versatile Ligands for Palladium‐Catalyzed Asymmetric Allylic Alkylation. Angew. Chem. Int. Ed. Engl., 1998, 37, 3116-3118.
[56]
Lam, K.S.; Hesler, G.A.; Gustavson, D.R.; Crosswell, A.R.; Veitch, J.M.; Forenza, S.; Tomita, K. Kedarcidin, a new chromoprotein antitumor antibiotic. I, Taxonomy of producing organism, fermentation and biological activity. Antibiotics1991, 44, 472-478 and Hofstead, S. J.; Matson, J. A.; Malacko, A. R.; Marquardt, H. Kedarcidin, a new chromoprotein antitumor antibiotic. II. Isolation, purification and physico-chemical properties. Antibiotics (Basel), 1992, 45, 1250-1254.
[62]
Gerber, T.I.A.; Bruwer, J.; Bandoli, G.; Perils, J.; du Preez, G.H. 1995.
[69]
van der Schaaf, P.A.; Boersma, J.; Smeets, W.J.J.; Spek, A.L.; van Koten, G. 1993.
[70]
Gerber, T.I.A.; Prils, T.; Du Preez, J.G.H.; Bandoli, G. 1997.
[71]
Koman, M.; Melnik, M. Crystal and molecular structure of bis (2, 6-dimethanolpyridine) copper (II) niflumate. Polyhedron1997, 16, 2721-2726. and Melnik, S. M.; Holloway, C. E. Spectral and magnetic properties of copper (ii) niflumate compounds with heterocyclic n-donor ligand. J. Coord. Chem., 1999, 49, 69-73.
[74]
Hoang, N.N.; Valach, F.; Dunaj-Jurco, M.; Melnik, M. Structure of bis (salicylato) bis (2-pyridylmethanol) copper (II). Acta Crystallogr. Sec. C, 1992, 48, 443-445.
[75]
Farfan, N.; Hopf, H. Crystal and molecular structure of., 1998.
[78]
Andac, O.; Guney, S.; Topcu, Y.; Yilmaz, V.T.; Horrison, W.T.A. Bis (pyridine-2,6-dimethanol-N,O,O′-cobalt(II)and–copper(II)disaccahrinate dihydrate: three-dimensional structures with extensive hydrogen bonds and aromatic π-π stacking interactions. Acta Crystallogr., 2002, C58, m17-m20.
[79]
Yilmaz, V.T.; Buney, S.; Andac, O.; Harrison, W.T.A. 2002.
[89]
Haratake, M.; Fukunaga, M.; Ono, M.; Nakayama, M. Synthesis of vanadium (IV, V) hydroxamic acid complexes and in vivo assessment of their insulin-like activity. J. Biol.Inorg. Chem. 2005, 10, 250-258. Crans, D.C.; Smee, J.J.; Gaidamauskas, E.; Yang, L. The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds. Chem. Rev., 2004, 104, 849-902.
[97]
Gielen, M.; Boualam, M.; Biesemans, M.; Mahieu, B.; Willem, R. 1992.
[98]
Gielen, M.; Joosen, E.; Mancilla, T.; Jurkschat, K.; Willem, R.; Roobol, C.; Bernheim, J. Platinum and other Metal Coordination Compounds in Cancer Chemotherapy; Nicolini, M., Ed.; Martinus Nijhoff, 1988.
[105]
Gupta, A.K.; Kim, J. 2003.
[107]
Powell, A.K. Metal Sites in Proteins and Models; Iron centers. Structure and Bonding, 1997, 88, 1-38. and references sited therein.
[110]
Tole, T.T.; Jordaan, J.H.L.; Vosloo, H.C.M. Synthetic Methods of α-pyridinyl and α-bipyridinyl Alcohols and α,α′-pyridine and α,α′-bipyridine Diols. Curr. Org. Synth., 2015, 12, 261-304.